VasoStitch, Inc. 's "Enabling TAVI” Platform for Nonsurgical Deployment of Transcatheter Therapies is Selected for Presentation at EuroPCR 2012
Published: Apr 17, 2012
DANVILLE, Calif.--(BUSINESS WIRE)--VasoStitch, a start-up medical technology company, announced today that its technology will be featured at “EuroPCR,” Europe’s most important interventional cardiology-focused annual scientific meeting of the year, on Thursday, May 17th, in Paris. VasoStitch is developing a percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an “open” surgical procedure.